Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian
1Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Abstract:
The National Comprehensive Cancer Network (NCCN) clinical practice guidelines have become the most recognized standard for clinical policy in cancer care. The Genetic Breast and Ovarian Guideline was introduced in 1999 with an emphasis on BRCA1/2. Based on evidence linking prostate cancer to the BRCA genes, prostate cancer was added to the guideline as a criterion for risk assessment in 2013. The current criteria include aggressive/metastatic disease and family history of BRCA-related cancers.
More Related Videos
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Cancer Prevention
Some...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mutagenicity and Carcinogenicity
